Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant
Novavax, Inc.'s (NASDAQ:NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European
Novavax's vaccine partners got permission to make a new version of their COVID vaccine to fight a newer virus variant starting next year. This shows their vaccine can adapt to new threats, which is important to watch as it means the company might have future customers.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.